PL2686421T3 - Generowanie komórek nk i progenitorów komórek nk - Google Patents

Generowanie komórek nk i progenitorów komórek nk

Info

Publication number
PL2686421T3
PL2686421T3 PL12711984T PL12711984T PL2686421T3 PL 2686421 T3 PL2686421 T3 PL 2686421T3 PL 12711984 T PL12711984 T PL 12711984T PL 12711984 T PL12711984 T PL 12711984T PL 2686421 T3 PL2686421 T3 PL 2686421T3
Authority
PL
Poland
Prior art keywords
cells
generation
cell progenitors
progenitors
cell
Prior art date
Application number
PL12711984T
Other languages
English (en)
Inventor
Jan Spanholtz
Harmen Dolstra
Original Assignee
Glycostem Therapeutics B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycostem Therapeutics B.V. filed Critical Glycostem Therapeutics B.V.
Publication of PL2686421T3 publication Critical patent/PL2686421T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL12711984T 2011-03-18 2012-03-16 Generowanie komórek nk i progenitorów komórek nk PL2686421T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NL2011050193 2011-03-18
EP11162866 2011-04-18
PCT/NL2012/050165 WO2012128622A1 (en) 2011-03-18 2012-03-16 Generation of nk cells and nk-cell progenitors
EP12711984.0A EP2686421B1 (en) 2011-03-18 2012-03-16 Generation of nk cells and nk-cell progenitors

Publications (1)

Publication Number Publication Date
PL2686421T3 true PL2686421T3 (pl) 2021-05-31

Family

ID=45928983

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12711984T PL2686421T3 (pl) 2011-03-18 2012-03-16 Generowanie komórek nk i progenitorów komórek nk

Country Status (7)

Country Link
US (1) US11118165B2 (pl)
EP (1) EP2686421B1 (pl)
CA (1) CA2830080C (pl)
DK (1) DK2686421T3 (pl)
ES (1) ES2856825T3 (pl)
PL (1) PL2686421T3 (pl)
WO (1) WO2012128622A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210076150A (ko) * 2012-08-13 2021-06-23 셀룰래리티 인코포레이티드 자연 살해 세포 및 그의 용도
CN105142651A (zh) 2013-02-05 2015-12-09 人类起源公司 来自胎盘的自然杀伤细胞
AU2014332022A1 (en) * 2013-10-08 2016-04-28 Nantkwest, Inc. Protocol and media for storage and transport of NK-92 cell line
CN104509529A (zh) * 2013-10-08 2015-04-15 康克韦斯特公司 用于储存和运输nk-92细胞系的方案和培养基
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
NZ741612A (en) * 2015-10-15 2022-12-23 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
US20190032013A1 (en) * 2016-01-29 2019-01-31 Tract Therapeutics, Inc. Immune cell selection, expansion, and use
BR112018072701A2 (pt) * 2016-05-07 2019-02-19 Celularity, Inc. métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais
GB201703476D0 (en) 2017-03-03 2017-04-19 Imp Innovations Ltd Natural killer cells
GB201704953D0 (en) 2017-03-28 2017-05-10 Imp Innovations Ltd Natural killer cells
JP6647240B2 (ja) 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
US11446329B2 (en) * 2017-11-01 2022-09-20 Restem Llc Natural killer cell adoptive transfer therapy for the elimination of senescent PBMCs, reduction of inflammatory cytokines and treatment of IBS
KR102265437B1 (ko) * 2017-11-24 2021-06-15 의료법인 성광의료재단 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
CN108315299A (zh) * 2018-02-13 2018-07-24 南京支云松生物科技有限公司 一种即用型异体nk细胞库网络储运应用系统
WO2019182392A1 (ko) * 2018-03-23 2019-09-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
SG11202104339WA (en) 2019-07-08 2021-05-28 Nantkwest Inc Mononuclear cell derived nk cells
CN114402065A (zh) * 2019-07-22 2022-04-26 格雷克斯迪姆医疗私人有限公司 低密度细胞培养
US20220333079A1 (en) * 2019-09-18 2022-10-20 Slbigen Inc. Genetically modified nk cell line transduced with gene encoding novel chimeric antigen receptor and use thereof
WO2021178890A1 (en) 2020-03-06 2021-09-10 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
CN111286488B (zh) * 2020-03-10 2021-04-02 河南侨创生命科技有限公司 一种自然杀伤细胞体外培养方法
US11547726B2 (en) * 2020-03-26 2023-01-10 Honed Life Sciences, Llc Enhancement of production of NK cells from stem cells
US20230214822A1 (en) * 2022-01-05 2023-07-06 Mastercard International Incorporated Computer-implemented methods and systems for authentic user-merchant association and services

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2502841T3 (es) * 2005-09-28 2014-10-06 Ipd-Therapeutics B.V. Métodos y medios para la proliferación de células madres y generación y expansión posterior de células progenitoras, así como producción de células efectoras como terapéuticos clínicos
CN101506356A (zh) * 2006-08-23 2009-08-12 比内克斯有限公司 用于免疫治疗的活化淋巴细胞的制备方法
EP2142642B1 (en) * 2007-03-27 2017-08-09 IPD-Therapeutics B.V. Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics
BR112012016203A2 (pt) * 2009-12-29 2019-09-24 Gamida Cell Ltd "métodos para melhoria da proliferaçõ e atividade das células exterminadoras naturais"
US20130059379A1 (en) 2010-02-24 2013-03-07 Ingo Schmidt-Wolf Method for the generation of a cik cell and nk cell population
US20200016198A1 (en) 2015-11-05 2020-01-16 Glycostem Therapeutics B.V. Composition for use in immunotherapy

Also Published As

Publication number Publication date
ES2856825T3 (es) 2021-09-28
EP2686421B1 (en) 2020-12-23
US11118165B2 (en) 2021-09-14
WO2012128622A1 (en) 2012-09-27
US20140080148A1 (en) 2014-03-20
CA2830080C (en) 2021-10-26
CA2830080A1 (en) 2012-09-27
EP2686421A1 (en) 2014-01-22
DK2686421T3 (da) 2021-03-08

Similar Documents

Publication Publication Date Title
PL2686421T3 (pl) Generowanie komórek nk i progenitorów komórek nk
IL254464A0 (en) Methods and systems for seeding cells
TWI563166B (en) Integrated generation systems and methods for generating power
EP2667881A4 (en) METHODS OF GENERATING IN VITRO INTERNAL EAR CELLS
ZA201402734B (en) Collector compositions and methods of using the same
GB2509009B (en) Power distribution in aircraft
IL230237B (en) Fat Cell Compounds and Methods
EP2724644A4 (en) CUSHION CELL AND CUSHION BODY USING THE SAME
EP2569430A4 (en) METHOD FOR PRODUCING ENTEROENDOKRINER CELLS FOR THE PRODUCTION AND DISTRIBUTION OF INSULIN
IL232879A0 (en) Production method for haploid cells, cells thus produced and their uses
GB201200458D0 (en) Methods of preparing cells and compositions
ZA201305116B (en) Fuel cells
HK1215719A1 (zh) 免疫抑制細胞及其製造和使用方法
EP2753346A4 (en) CERAMIDASE AND CELL DIFFERENTIATION
IL229176A0 (en) Preparations of living cells and their uses
ZA201405932B (en) Energy plant and parts of an energy plant
EP2970915A4 (en) METHOD AND COMPOSITIONS FOR PRODUCING STABILIZED TRANSFECTED CELLS
HRP20200794T8 (hr) Keramidaza i diferencijacija stanica
EP2939238B8 (en) Clock generation and delay architecture
IL220217B (en) Connector with active shielding
EP2660314A4 (en) IPS CELLS AND METHOD FOR THEIR PRODUCTION
EP2830131A4 (en) CELL STRUCTURE OF FUEL CELL
GB201121170D0 (en) Galvanic cells and components therefore
EP2932536A4 (en) COMPOSITIONS AND METHODS FOR IMPROVED SOLAR CELLS
IL246448A0 (en) Preparations and methods for transferring active telomerase to cells in vivo